![](https://news.europawire.eu/wp-content/uploads/2023/11/Boehringer-Ingelheim-Leverages-IBMs-AI-Tech-for-Novel-Antibody-Development-144x144.jpg)
(IN BRIEF) Boehringer Ingelheim and IBM have formed a partnership to expedite the discovery of novel candidate antibodies for therapeutic purposes. Boehringer will utilize IBM’s foundation model technologies, combining them with their proprietary data to enhance the antibody discovery process. … Read the full press release